Get the Stockscreener App
1.17
3.31%
-0.04
Mira Pharmaceuticals Inc stock is traded at $1.17, with a volume of 206.28K.
It is down -3.31% in the last 24 hours and up +10.38% over the past month.
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
See More
Previous Close:
$1.21
Open:
$1.22
24h Volume:
206.28K
Relative Volume:
0.15
Market Cap:
$19.38M
Revenue:
-
Net Income/Loss:
$-12.78M
P/E Ratio:
-1.3273
EPS:
-0.8815
Net Cash Flow:
$-4.71M
1W Performance:
+0.00%
1M Performance:
+10.38%
6M Performance:
+69.86%
1Y Performance:
+40.90%
1-Day Range:
$1.15
$1.23
1-Week Range:
$1.14
$1.2546
52-Week Range:
$0.51
$5.01
Mira Pharmaceuticals Inc Stock (MIRA) Company Profile
Name
Mira Pharmaceuticals Inc
Sector
Industry
Phone
813-369-5150
Address
1200 BRICKELL AVENUE, MIAMI
Compare MIRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MIRA
Mira Pharmaceuticals Inc
|
1.17 | 19.38M | 0 | -12.78M | -4.71M | -0.8815 |
|
LLY
Lilly Eli Co
|
742.35 | 705.53B | 40.86B | 8.37B | -2.28B | 9.25 |
|
NVO
Novo Nordisk Adr
|
81.03 | 359.79B | 39.36B | 13.79B | 9.83B | 3.086 |
|
JNJ
Johnson Johnson
|
148.15 | 344.63B | 87.70B | 14.68B | 19.03B | 6.05 |
|
ABBV
Abbvie Inc
|
172.61 | 305.03B | 55.53B | 5.12B | 15.62B | 2.88 |
|
MRK
Merck Co Inc
|
96.24 | 251.88B | 63.17B | 12.15B | 14.84B | 4.77 |
Mira Pharmaceuticals Inc Stock (MIRA) Latest News
International Assets Investment Management LLC Invests $29,000 in MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) - Defense World
MIRA Pharmaceuticals (NASDAQ:MIRA) Shares Down 1.7% – Should You Sell? - Defense World
AMRN Stock Rises Over 5% Amidst Lack of Institutional Ratings - GuruFocus.com
Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation - Yahoo Finance
Zacks Small Cap Has Pessimistic Outlook of MIRA Q4 Earnings - Defense World
Mira Pharmaceuticals appoints new accounting firm By Investing.com - Investing.com South Africa
Mira Pharmaceuticals appoints new accounting firm - Investing.com
Why Wall Street Expects This Growth Stock To Soar 99% In 2025 - Barchart
Should You Buy Joby Aviation Stock While It's Below $10? - Barchart
C3.ai Stock: Buy, Sell, Or Steer Clear? - Barchart
Is Xcel Energy Stock Underperforming The Nasdaq? - Barchart
2 Fantastic Beaten-Down Growth Stocks Down 35% And 21% To Buy - Barchart
Missed Out on Nvidia: 1 No-Brainer Artificial Intelligence (AI) Stock to Buy Before It Crushes the Market in 2025, and Beyond - Barchart
MIRA Pharmaceuticals Submits IND for Ketamir-2, Targeting Unmet Needs in Neuropathic Pain Treatment - Barchart
MIRA Pharmaceuticals Submits IND for Ketamir-2On December 19, 2024, MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) disclosed that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Ketamir-2, - Defense World
Stocks In Play: Canacol Energy Ltd. - Barchart
Grain Spreads: Profit Taking Theme - Barchart
Stocks Rally On Dovish PCE Inflation Report - Barchart
The Current State Of HR Is Unacceptable - Barchart
Gilead Stock Gains 15.4% In A Year: Should You Buy, Sell Or Hold? - Barchart
Is Alexandria Real Estate Stock Underperforming The Nasdaq? - Barchart
Is W.R. Berkley Stock Outperforming The Dow? - Barchart
PayPal Rises 40% In A Year: To Buy Or Not To Buy The PYPL Stock? - Barchart
US proposes voluntary guidelines for self-driving vehicles in waning days of Biden administration - Barchart
Takeaways From The Associated Press’ Reporting On Prison Labor In Alabama - Barchart
Arabica Coffee Recovers On Weaker Dollar And Smaller Brazilian Crop - Barchart
Medtronic Stock Declines 5.6% In A Month: Time To Buy The Dip? - Barchart
Is PPG Industries Stock Underperforming The S&P 500? - Barchart
Stocks Regain Footing On Dovish PCE Inflation Report - Barchart
Enterprise Products Stock Rises 25% YTD: Should You Buy Now Or Avoid It? - Barchart
Three Reasons Why PESI Is Risky And One Stock To Buy Instead - Barchart
SCARBOROUGH INNOVATES PARTNERS WITH SUNRAY VENTURE CAPITAL TO ACCELERATE LOCAL STARTUPS WITH 'CATALYST IGNITE' - Barchart
Knightscope K7 Alpha Testing Underway And 2024 Recap - Barchart
Take-Two (NASDAQ:TTWO): Strongest Q3 Results From The Video Gaming Group - Barchart
Stocks Pare Losses on Dovish PCE Report, But Threats Remain from Triple-Witching and Government Shutdown - Barchart
Q3 Video Conferencing Earnings: Five9 (NASDAQ:FIVN) Earns Top Marks - Barchart
3 Reasons To Sell BALY And 1 Stock To Buy Instead - Barchart
Rude Faces Holiday Volatility Amid Fed Policy, G-7 Sanction Talks, And Lower Liquidity - Barchart
Crude Faces Holiday Volatility Amid Fed Policy, G-7 Sanction Talks, And Lower Liquidity - Barchart
2025 Picks: 2 Stocks To Buy Now For 50% Upside - Barchart
Three Reasons Why GPRO Is Risky And One Stock To Buy Instead - Barchart
Beyond Reality: Investing In AR/VR Tech For Future Gains - Barchart
Federal Reserve's Preferred Inflation Gauge Shows Price Pressures Eased Last Month - Barchart
The number of Americans applying for unemployment benefits falls significantly after last week's big jump - Barchart
MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development - AccessWire
MIRA Pharmaceuticals Submits FDA Application for Breakthrough Pain Treatment Targeting $3.1B Market - StockTitan
3 Best Industrials Sector Picks For Long-Term Investors In 2025 - Barchart
EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment - Benzinga
US stocks fall sharply and Dow tumbles 1,100 points after the Fed hints at just 2 rate cuts for 2025 - Barchart
OUTFRONT Media Stock Rises 33% In 6 Months: Will The Trend Last? - Barchart
Three Reasons To Avoid R And One Stock To Buy Instead - Barchart
Mira Pharmaceuticals Inc Stock (MIRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.22%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):